Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

GRAPPA 2022 Psoriasis Questionnaire Might Identify Risk of Axial Disease A patient-completed questionnaire shows promise for detecting risk of undiagnosed axial involvement in psoriasis. MDedge News, ...

Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA). Biological agents were found more effective than methotrexate in preventing psoriatic ...

GRAPPA 2022 Novel PsA Treatment Choice Algorithm Uses T-Cell Behavior A novel treatment algorithm for psoriatic arthritis (PsA) is being developed to provide more precise biologic choices. Medscape ...

Patients with psoriatic arthritis who received bimekizumab demonstrated sustained improvements in clinical outcomes for up to 52 weeks, with or without the use of concomitant methotrexate. Patients ...

Please provide your email address to receive an email when new articles are posted on . EULAR recommendations on pharmacological PsA management cover all available drugs in a “practical and ...

Methotrexate is a strong medicine. The FDA approved it to treat adults with severe, disabling psoriasis that cannot be controlled with medicine applied to the skin or light treatments. Methotrexate ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, creating a condition that challenges patients and clinicians alike. This ...